RENAAL

RENAAL

Nephrology A clinical trial–Reduction in Endpoints in patients with Non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan. See Losartan.
Mentioned in ?
References in periodicals archive ?
The RENAAL study revealed a lower cardiovascular event rate was seen is patients with bigger reductions in the urinary albumin excretion.
Vart P, Scheven L, Heerspink HJ, de Jong PE, de Zeeuw D, Gansevoort RT, PREVEND Study Group, RENAAL Investigators.
Parving et al., "Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL," Kidney International, vol.
de Zeeuw et al., "The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study," Kidney International, vol.
(23.) Brenner BM, Cooper ME, de Zeeuw D, et al; RENAAL Study Investigators.
Perna et al., "Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results," Journal of the American Society of Nephrology, vol.
Lyle, "Recent advances in management of type 2 diabetes and nephropathy: Lessons from the RENAAL study," American Journal of Kidney Diseases, vol.
Lyleet al., "Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study," Clinical Journal of the American Society of Nephrology, vol.
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.
Based on the results of four major renal outcome studies (Micro-HOPE, IRMA-2, RENAAL, IDNT studies), the American diabetes association has recommended ARBs for treatment of overt diabetic nephropathy, whereas patients with only microalbuminuria are recommended to be treated with either ACE inhibitors or ARBs10,11.
For the RENAAL Study Group Effects of Blood Pressure Level on Progression of Diabetic Nephropathy.